Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 10,845 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Not applicable Interventional

A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous Levels

NCT04564885
View directory record Official record
Conditions
Cervical Disc Disease
Interventions
BAGUERA®C Cervical Disc Prosthesis, Mobi-C Cervical Disc
Device
Lead sponsor
Spineart USA
Industry
Eligibility
22 Years to 69 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational

Ask Suicide-Screening Questions (ASQ) for Youth With Autism Spectrum and Neurodevelopmental Disorders

NCT04317118
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

NCT02819297
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, CIC
Interventions
BLI400 Laxative, BLI400 Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

NCT03036904
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847
View directory record Official record
Conditions
Frail Elderly, Aging, Immune Function, Muscle Function
Interventions
Ketone ester, Placebo Comparator: Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Novato, California • Farmington, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00099125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
118
States / cities
Phoenix, Arizona • Burbank, California • Fresno, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Dexamethasone in Cryptococcal Meningitis

NCT00000776
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Not applicable Interventional Results available

Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)

NCT00289289
View directory record Official record
Conditions
Atrial Fibrillation, Tachycardia, Supraventricular, Arrhythmia, Bradycardia
Interventions
Intervention Pacing Features
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Little Rock, Arkansas • Rancho Mirage, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06176768
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LY3972406, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406
View directory record Official record
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00082433
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions
Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting No phase listed Observational

Pivotal Study for the Cardiac Performance System (CPS)

NCT06870591
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Cardiac Performance System (CPS)
Device
Lead sponsor
Sensydia Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Timeline
2025 – 2026
U.S. locations
10
States / cities
Huntsville, Alabama • Evanston, Illinois • Hackensack, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Early Phase 1 Interventional

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

NCT07144826
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions
Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

NCT04301076
View directory record Official record
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

NCT02258217
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Acthar
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Phase 2 Interventional

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

NCT05333458
View directory record Official record
Conditions
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Selinexor
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate MEDI-534 in Healthy Adults

NCT00111878
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Interventions
MEDI-534
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2007 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Nicotine Product Messaging to Communicate Risk of Use for Young Adults

NCT07702435
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Behavioral Intervention, Survey Administration
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 30 Years
Enrollment
607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 9:24 PM EDT